AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
February 29 2008 - 12:00PM
PR Newswire (US)
QUEBEC CITY, Feb. 29 /PRNewswire-FirstCall/ -- AEterna Zentaris
Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company
focused on endocrine therapy and oncology, today announced the
resignation of Mario Paradis, CA, the Company's Senior Vice
President, Administrative & Legal Affairs and Corporate
Secretary. Mr. Paradis has accepted the position of Vice President
and Chief Financial Officer of Atrium Innovations, a leading
developer, manufacturer and marketer of science-based products for
the cosmetics, pharmaceutical, chemical and nutrition industries.
Mr. Paradis will remain in his capacity at the Company through a
transition period, and his departure will become effective in early
April. David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris
commented, "We would like to extend our sincere appreciation to
Mario for his dedication and significant contributions to the
evolution of AEterna Zentaris over the years. We wish him well as
he embarks on this new chapter in his career." About AEterna
Zentaris Inc. AEterna Zentaris Inc. is a global biopharmaceutical
company focused on endocrine therapy and oncology with proven
expertise in drug discovery, development and commercialization.
News releases and additional information are available at
http://www.aezsinc.com/. Forward-Looking Statements This press
release contains forward-looking statements made pursuant to the
safe harbor provisions of the U.S. Securities Litigation Reform Act
of 1995. Forward-looking statements involve known and unknown risks
and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability
of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments except if
we are requested by a governmental authority or applicable law.
DATASOURCE: AETERNA ZENTARIS INC. CONTACT: Jenene Thomas, Senior
Director, Investor Relations & Corporate Communications, (908)
626-5509, ; Paul Burroughs, Media Relations, (418) 652-8525, ext.
406,
Copyright